S. Lindsey Davis

University of Colorado Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index900citations31works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(6), Cancer Immunotherapy and Biomarkers(5), Tuberculosis Research and Epidemiology(4), COVID-19 Clinical Research Studies(4), SARS-CoV-2 and COVID-19 Research(3)

Publications31 total

An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).
Journal of Clinical Oncology·2024· 3 cited
Management of Metastic Liver Cancer
2024Open Access
1179: EFFICACY OF IVABRADINE IN IMPROVING OXYGENATION IN VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION
Critical Care Medicine·2023· 1 cited
1075 Community Outpatient Orthopaedic Clinics; a Post Pandemic Model of Care
British journal of surgery·2023Open Access
Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells
iScience·2023· 23 citedOpen Access
Suppl Figure 6 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Table 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Supplementary Figure Legends from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Communications Biology·2022· 79 citedOpen Access
Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation
2022· 10 citedOpen Access
Quantification of Infectious SARS-CoV-2 by the 50% Tissue Culture Infectious Dose Endpoint Dilution Assay
Methods in molecular biology·2022· 28 citedOpen Access
Dynamic Single-Cell RNA Sequencing Reveals that Intravenous BCG Vaccination Curtails SARS-CoV-2 Induced Disease Severity and Lung Inflammation
SSRN Electronic Journal·2022Open Access
Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses
2021· 19 citedOpen Access
Pharmacology and Pharmacokinetics of Opioids in the ICU
2021
Abstract 6647: Sensitizing microsatellite stable colorectal cancer to immune checkpoint therapy utilizing Wnt pathway inhibition
Cancer Research·2020· 3 cited
Abstract 1315: Combination of Wee1 inhibition with targeted and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma
Experimental and Molecular Therapeutics·2019
Abstract 3855: Preclinical investigation of novel ALDH1A1 inhibitors in pancreatic cancer
Cancer Research·2019
page 1 of 2Next →

Frequent Co-authors

Todd M. Pitts(13), Sanjay K. Jain(10), William R. Bishai(7), Christopher H. Lieu(7), Aik Choon Tan(7), John J. Tentler(7), Stacey M. Bagby(6), Wells A. Messersmith(6), Lindsey N. Micel(6), Heather M. Selby(6), Kelsey L. Brunkow(6), Kelli M. Robertson(6), Peter J. Klauck(6), Esha Gangolli(6), Robyn Fabrey(6), Shawn M. O’Connell(6), Patrick W. Vincent(6), Peter Um(5), Alvaro A. Ordoñez(5), C. Korin Bullen(5)